Trial reportEuropean journal of nutrition2025
Supplementation with resveratrol modified gut microbiota improving insulin sensitivity and lipid metabolism in subjects with obesity and insulin resistance.
Trial report in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeWith the global burden of obesity and metabolic syndrome, new strategies to prevent some of its complications, in particular insulin resistance, are being evaluated. Thus, the aim of this study was to assess the effects of resveratrol supplementation on insulin sensitivity, body composition, skeletal muscle metabolism, and gut microbiota composition in individuals with obesity and insulin resistance.
methodsThirty-two participants were randomized to receive either resveratrol or placebo for two months. At the beginning and end of the study body composition, an oral glucose tolerance (OGTT), serum biochemical and a fecal sample were obtained. At the end of the study a skeletal muscle biopsy was performed to assess by immunoblots the abundance of some proteins and to carry out histological analysis.
resultsThere was an increase in lean mass in participants of the resveratrol group. Notably, serum insulin and triglycerides significantly decreased in the resveratrol group compared to placebo. OGTT testing revealed a significant reduction in insulin area under the curve only in the resveratrol group, indicating improved insulin sensitivity. At the molecular level, resveratrol intake increased in skeletal muscle adenosine monophosphate-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) phosphorylation, peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC1α) expression, and succinate dehydrogenase (SDH) activity, suggesting enhanced mitochondrial function. Resveratrol significantly altered gut microbiota composition, increasing alpha diversity and some beneficial genera. Correlation analyses revealed inverse associations between enriched microbial genera and serum triglycerides, insulin, and HOMA-IR.
conclusionResveratrol supplementation improved insulin sensitivity and lipid metabolism associated with enhanced skeletal muscle oxidative capacity and favorable changes in gut microbiota composition.
Indexed as
Identifiers
41359054What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.